RESEARKA

The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

Citation Support

• source_1 Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
• source_2 Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL
• source_3 Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
• source_4 Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
• source_5 Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML